10583
document
Treatment of canine parvoviral enteritis with interferon-omega in a placebo-controlled challenge trial . Canine parvoviral enteritis continues to cause significant morbidity and mortality in dogs worldwide , and efficacious antiviral therapies are lacking . The present trial was aimed at evaluating the therapeutic efficacy of a recombinant feline interferon ( type omega ) preparation in the treatment of parvoviral enteritis in dogs . A double-blind , placebo-controlled challenge trial was performed in beagle pups ( 8-9 weeks ) ; clinical signs , body weight , hematologic parameters , and mortality were monitored for a period of 14 days after challenge . Fourteen animals were inoculated with virulent canine parvovirus ; 10 animals that developed clinical signs thereby meeting the inclusion criteria were admitted to the treatment phase in two randomly selected groups ( placebo and IFN ) of equal size . The IFN group received daily intravenous injections of rFeIFN-omega ( 2.5 MU/kg ) for three consecutive days . The placebo group received daily injections of saline without IFN . Both groups of animals received individual supportive treatment consisting of adjusted diet and electrolyte solution . All five dogs in the placebo group developed fulminating enteritis with typical clinical signs and died within 10 days post-inoculation ( or 6 days post-treatment ) . In the IFN-treated group , one animal died on day 2 after the treatment was started , whereas the other four dogs survived the challenge and gradually recovered . Our data confirm that the rFeIFN-omega can exert a significant therapeutic effect on dogs with parvoviral enteritis by improving clinical signs and reducing mortality .
10584
Intervention_Pharmacological
interferon-omega
10585
Intervention_Pharmacological
antiviral therapies
10586
Intervention_Pharmacological
recombinant feline interferon ( type omega )
10587
Intervention_Pharmacological
inoculated with virulent canine parvovirus
10588
Intervention_Control
placebo
10589
Intervention_Pharmacological
IFN
10590
Intervention_Pharmacological
rFeIFN-omega
10591
Intervention_Control
placebo
10592
Intervention_Pharmacological
saline
10593
Intervention_Pharmacological
rFeIFN-omega
10594
Outcome_Physical
fulminating enteritis with typical clinical signs
10595
Outcome_Mortality
died
10596
Outcome_Mortality
died
10597
Outcome_Mortality
survived
10598
Outcome_Physical
recovered
10599
Participant_Condition
canine
10600
Participant_Condition
Canine parvoviral enteritis
10601
Participant_Condition
dogs
10602
Participant_Condition
parvoviral enteritis in dogs
10603
Participant_Condition
pups
10604
Participant_Age
( 8-9
10605
Participant_Sample-size
Fourteen
10606
Participant_Condition
virulent canine parvovirus
10607
Participant_Sample-size
10
10608
Participant_Condition
dogs
10609
Participant_Condition
parvoviral enteritis